Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Retained Earnings (2016 - 2025)

Theravance Biopharma (TBPH) has disclosed Retained Earnings for 12 consecutive years, with -$920.7 million as the latest value for Q3 2025.

  • On a quarterly basis, Retained Earnings rose 3.09% to -$920.7 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$920.7 million, a 3.09% increase, with the full-year FY2024 number at $7000.0, changed N/A from a year prior.
  • Retained Earnings was -$920.7 million for Q3 2025 at Theravance Biopharma, down from -$10000.0 in the prior quarter.
  • In the past five years, Retained Earnings ranged from a high of $8000.0 in Q2 2021 to a low of -$1.8 billion in Q2 2022.
  • A 5-year average of -$674.1 million and a median of -$876.0 million in 2023 define the central range for Retained Earnings.
  • Peak YoY movement for Retained Earnings: skyrocketed 100.0% in 2021, then crashed 22002350.0% in 2022.
  • Theravance Biopharma's Retained Earnings stood at -$1.7 billion in 2021, then skyrocketed by 100.0% to -$15000.0 in 2022, then tumbled by 1400.0% to -$225000.0 in 2023, then surged by 103.11% to $7000.0 in 2024, then tumbled by 13152257.14% to -$920.7 million in 2025.
  • Per Business Quant, the three most recent readings for TBPH's Retained Earnings are -$920.7 million (Q3 2025), -$10000.0 (Q2 2025), and -$979.1 million (Q1 2025).